NRx Pharmaceuticals to Announce Third Quarter Financial Results
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is gearing up to report its third quarter financial results. The announcement will occur before market opening, offering a glimpse into the company's performance and outlook.
Details of the Financial Results Release
The financial results are expected to be released via press release on November 17. Investors and stakeholders can find more information on NRx's official website, ensuring they have access to the latest updates regarding the company’s financial health.
Conference Call to Discuss Financial Insights
Along with the financial results, NRx will host a conference call at 8:30am ET on the same day. This call aims to provide a comprehensive corporate and financial update, along with an overview of future operations and growth strategy, spotlighting the company’s direction in biopharmaceutical developments.
Accessing the Conference Call
Participants can join the live conference call by telephone. Domestic callers can reach the call by dialing 1-800-717-1738, while international participants can dial +1-646-307-1865. Those unable to join can access a webcast of the call through NRx's website, allowing shareholders and interested parties an opportunity to stay informed.
About NRx Pharmaceuticals
NRx Pharmaceuticals is dedicated to innovating therapies that target central nervous system disorders, such as suicidal depression, chronic pain, and PTSD. The company is advancing its proprietary NMDA platform through candidates like NRX-100, an intravenous ketamine therapy, and NRX-101, a combination treatment aimed at enhancing patient outcomes in relevant psychiatric conditions.
Innovative Therapeutics Under Development
Currently, NRX-100 has received Fast Track Designation from regulatory agencies, demonstrating its potential in treating suicidal ideation, especially related to bipolar depression. Moreover, NRX-101 is on the fast track with a Breakthrough Therapy Designation, highlighting its importance in addressing challenging conditions faced by patients.
Future Regulatory Filings
Recently, NRx Pharmaceuticals has re-filed for an Abbreviated New Drug Application (ANDA) and is also preparing a New Drug Application for NRX-100. This includes a focus on securing a Commissioner’s National Priority Voucher, further illustrating NRx's commitment to developing and providing solutions for those suffering from significant mental health challenges.
Contact Information
For further inquiries, interested parties can reach out to:
- Matthew Duffy, Co-CEO, Chief Business Officer, NRx Pharmaceuticals, Inc., Email: mduffy@nrxpharma.com
- Brian Korb, Managing Partner, astr partners, Email: brian.korb@astrpartners.com
- Telephone: Brian Korb’s direct line: (917) 653-5122
Frequently Asked Questions
What is the date of NRx Pharmaceuticals' financial results release?
NRx Pharmaceuticals plans to release its financial results on November 17.
What time is the conference call scheduled for?
The conference call will begin at 8:30am ET on the same day as the financial results release.
How can I access the conference call?
Participants can access the call via phone or a live webcast on the company's website.
What are NRX-100 and NRX-101?
NRX-100 is an intravenous ketamine therapy, while NRX-101 is an oral combination treatment aimed at addressing severe mood disorders.
What designations has NRx received for its therapies?
NRX-100 has received Fast Track Designation, and NRX-101 is recognized as a Breakthrough Therapy, showcasing their potential impact in treating mental health conditions.
